May 4, 2015—CBSET, a not-for-profit preclinical research institute, announced that its scientists have published data and analyses that provide critical insights into the predictability, variability, and treatment success of catheter-based renal denervation (RDN) therapy. These data suggest that new, optimal alternative devices compared to first-generation RDN systems may enhance or assure efficacy, stated CBSET.
The study, “Arterial Microanatomy Determines the Success of Energy-Based Renal Denervation in Controlling Hypertension,” was published by Abraham Rami Tzafriri, PhD, et al in Science Translational Medicine, a publication of the American Association for the Advancement of Science (2015;7:285).